• Jefferies sets a price target of $8 for NASDAQ:MLTX, indicating a potential increase of about 32.97% from its current price.
• RBC analysts drastically reduce their target price from $67 to $10 per share following disappointing trial results for sonelokimab.
• Despite a drop of over 90% in MLTX shares, RBC sees potential for sonelokimab with a market opportunity of around $1 billion if regulatory approval is obtained.

MoonLake Immunotherapeutics (NASDAQ: MLTX) is a biopharmaceutical company focused on developing innovative treatments for inflammatory diseases. Recently, Jefferies set a price target of $8 for NASDAQ:MLTX, suggesting a potential price increase of about 32.97% from its current price of $6.02. This comes amid significant challenges for the company.

RBC analysts have drastically reduced their target price for MLTX from $67 to $10 per share, following disappointing trial results for sonelokimab, a treatment for skin disease. The stock was downgraded from ‘Outperform’ to ‘Sector Perform’ due to a reduced market opportunity and the need for further clarity, as highlighted by RBC.

The trial results showed sonelokimab's effectiveness ranged between 9-17%, which is not competitive with existing treatments. Despite this, RBC analysts see potential for the drug, estimating it could be sold for around $1 billion if regulatory approval and future data are favorable.

Following these developments, MLTX shares have dropped over 90%, trading at $6.08. The Phase 3 VELA-1 and VELA-2 trials, which enrolled 838 patients, assessed the efficacy of sonelokimab using HiSCR75 as the primary endpoint. The trials compared a 120mg dose of sonelokimab to a placebo.

Currently, MLTX is priced at $6.25, having decreased by approximately 89.93% from its 52-week high of $62.75. The stock has fluctuated between $5.96 and $7.13 today, with a market capitalization of about $396.57 million and a trading volume of 78.42 million shares.